公开(公告)号：KR1020090038336A

公开(公告)日：2009-04-20

申请号：KR1020070103779

申请日：2007-10-15

Applicant: 가톨릭대학교 산학협력단 ,  포항공과대학교 산학협력단

Inventor： 김호연 ,  조미라 ,  강창민 ,  문영미 ,  성영철 ,  김두진

IPC: A61K38/20

CPC classification number: A61K38/20 ,  A61K38/1722 ,  C07K14/4717 ,  C07K14/54 ,  C12N15/62 ,  C12N15/63 ,  Y10S424/809 ,  Y10S424/81

Abstract: A pharmaceutical composition containing Interleukin-27, Il-27-Fc fusion protein and mutant thereof is provided to efficiently inhibit production of IL-17 and increase production of IFN-gamma by promoting differentiation of Th-1 in order to treat and prevent autoimmune diseases. A pharmaceutical composition for treatment and prevention of autoimmune diseases comprises Interleukin-27, Il-27-Fc fusion protein and mutant thereof. The Interleukin-27 is human-derived proteins. The pharmaceutical composition contains Il-27-Fc fusion protein wherein carboxyl terminal of the Interleukin-27 is coupled with amino terminal of immunoglobulin Fc and peptide. The immunoglobulin Fc is derived from one selected from the group consisting of IgG, IgA, IgM, IgE and IgD. The immunoglobulin Fc has a hinge site which can has one or more cysteins. The autoimmune diseases represent systemic lupus erythematosus, Sjogren syndrome, Hashimoto thyroiditis, rheumatoid arthritis, polymyositis, scleroderma, Addison disease, vitiligo, pernicious anemia, glomerulonephritis or pulmonary fibrosis.

Abstract translation: 提供了含有白细胞介素-27，II-27-Fc融合蛋白及其突变体的药物组合物，以有效抑制IL-17的产生并通过促进Th-1的分化来增加IFN-γ的产生，从而治疗和预防自身免疫疾病 。 用于治疗和预防自身免疫疾病的药物组合物包含白细胞介素-27，II-27-Fc融合蛋白及其突变体。 白细胞介素-27是人源性蛋白质。 药物组合物含有II-27-Fc融合蛋白，其中白细胞介素-27的羧基末端与免疫球蛋白Fc和肽的氨基末端偶联。 免疫球蛋白Fc来自选自IgG，IgA，IgM，IgE和IgD的一种。 免疫球蛋白Fc具有可以具有一个或多个半胱氨酸的铰链位点。 自身免疫性疾病代表系统性红斑狼疮，干燥综合征，桥本甲状腺炎，类风湿性关节炎，多发性肌炎，硬皮病，艾迪生病，白癜风，恶性贫血，肾小球性肾炎或肺纤维化。

公开(公告)号：KR1020160123901A

公开(公告)日：2016-10-26

申请号：KR1020150054725

申请日：2015-04-17

Applicant: 포항공과대학교 산학협력단

Inventor： 박문녀 ,  조동우 ,  문영미 ,  장진아 ,  김현지

IPC: A61L27/36

CPC classification number: A61L27/3687 ,  A61L27/3604 ,  A61L2430/16 ,  A61L2430/40 ,  B33Y10/00 ,  B33Y70/00 ,  B33Y80/00

Abstract: 본발명에따른생체적합성각막생성방법은조직원으로부터각막을절개하여제공하는단계; 상기제공된각막의세포외기질을숯(charcoal)이포함된정제수에넣고소정의시간동안탈세포처리하는단계; 및상기처리된각막의세포외기질을저장액(hypotonic solution)내에서교반하여후처리하는단계를포함한다. 본발명에따른생체적합성각막생성방법은각막의탈세포화처리제로숯(charcoal)을사용하여, 원형각막의세포외기질과동일한조직재생을가능하게하는효과가있다. 또한, 면역거부반응이없는각막생성및 상기각막의이식을통한환자의빠른재생효과를기대할수 있는효과가있다.

公开(公告)号：KR101717234B1

公开(公告)日：2017-03-27

申请号：KR1020150054725

申请日：2015-04-17

Applicant: 포항공과대학교 산학협력단

Inventor： 박문녀 ,  조동우 ,  문영미 ,  장진아 ,  김현지

IPC: A61L27/36

CPC classification number: A61L27/3687 ,  A61L27/3604 ,  A61L2430/16 ,  A61L2430/40 ,  B33Y10/00 ,  B33Y70/00 ,  B33Y80/00

Abstract: 본발명에따른생체적합성각막생성방법은조직원으로부터각막을절개하여제공하는단계; 상기제공된각막의세포외기질을숯(charcoal)이포함된정제수에넣고소정의시간동안탈세포처리하는단계; 및상기처리된각막의세포외기질을저장액(hypotonic solution)내에서교반하여후처리하는단계를포함한다. 본발명에따른생체적합성각막생성방법은각막의탈세포화처리제로숯(charcoal)을사용하여, 원형각막의세포외기질과동일한조직재생을가능하게하는효과가있다. 또한, 면역거부반응이없는각막생성및 상기각막의이식을통한환자의빠른재생효과를기대할수 있는효과가있다.